芬兰成年人的摄入量,尿液度和肥胖之间的关联:基于人口的研究
Annika Santalahti1, Tarja Inkeri Kinnunen2, Satu Männistö1
1Department of Public Health, Finnish Institute for Health and Welfare, Helsinki, Finland.
Nutrition and health
|March 5, 2026
概括
高摄入量与芬兰成年人普遍和腹部肥胖的几率增加有关. 这项研究强调了芬兰饮食中的与肥胖风险之间的关联.
科学领域:
- 营养科学 营养科学
- 公共卫生 公共卫生
- 流行病学 流行病学
背景情况:
- 越来越多的证据将摄入量与肥胖风险联系在一起.
- 芬兰的消耗量历史上一直很高,并采取了减少盐分的举措.
- 芬兰对摄入量和肥胖的研究是有限的.
研究的目的:
- 调查芬兰成年人摄入量与肥胖之间的关联.
- 为了检查点尿度和肥胖之间的关系.
- 评估与摄入量相关的一般和腹部肥胖症.
主要方法:
- 全国金融健康2017年研究数据的横截面分析.
- 通过食物频率调查问卷估计的食.
- 在子样本中测量的点尿度;通过BMI和腰围评估的一般和腹部肥胖.
主要成果:
- 摄入量最高的女性患一般 (OR 4.30) 和腹部肥胖 (OR 3.42) 的几率增加.
- 尿中度最高的男性患一般 (OR 6.05) 和腹部肥胖 (OR 4.68) 的几率增加.
- 斑点尿样显示了与24小时收集的适度一致 (斯皮尔曼的rho=0.45).
结论:
- 饮食中较高的摄入量和尿液度与一般和腹部肥胖的几率增加有关.
- 研究结果表明,芬兰成年人中和肥胖之间存在联系.
- 需要进一步的前性研究来确认因果关系并阐明生物机制.
相关概念视频
Drug Dosing: Obese Patients
320
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
320
Obesity
1.5K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
492
Management of renal calculi focuses on effective strategies like tailored nutrition and hydration therapy. Adjusting diet and fluid intake reduces stone formation and recurrence, making these interventions simple yet powerful in kidney stone prevention and management.Understanding Kidney StonesKidney stones form when calcium, oxalate, uric acid, and cystine concentrate and crystallize in urine. Factors contributing to their formation include genetic predisposition, certain medical conditions,...
492
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
331
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
331
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
259
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
259


